Jefferies analyst Akash Tewari maintains $argenx SE (ARGX.US)$ with a buy rating, and maintains the target price at $689.
According to TipRanks data, the analyst has a success rate of 44.3% and a total average return of 10.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
The decision to proceed to Phase 3 across all three myositis subtypes is viewed favorably and is seen as bolstering the future value of the pipeline, although it may not significantly impact stock movement. Currently, the model has been updated to incorporate a 70% probability of success for myositis, with adjustments anticipated following the full data reveal at an upcoming medical conference.
After Argenx announced clinical proof-of-concept in myositis, with subQ efgart demonstrating statistically significant improvements across all three myositis subtypes in Phase 2, it is anticipated that broader leadership in the autoimmune category could be solidified. Detailed results are expected to be shared at a future medical meeting.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Akash Tewari維持$argenx SE (ARGX.US)$買入評級，維持目標價689美元。
根據TipRanks數據顯示，該分析師近一年總勝率為44.3%，總平均回報率為10.3%。
此外，綜合報道，$argenx SE (ARGX.US)$近期主要分析師觀點如下：
繼續進行所有三種肌炎亞型的第三階段決定受到良好評價，並被認爲會增強管道的未來價值，儘管可能不會對股票走勢產生重大影響。目前，模型已經更新，將肌炎成功概率調整爲70％，預計在即將舉行的醫療會議上披露完整數據後將進行調整。
在Argenx宣佈肌炎的臨床概念證明後，通過皮下注射Efgart在第2階段顯示出在所有三種肌炎亞型中具有統計學意義的改善，預期在自身免疫疾病類別中可能鞏固更廣泛的領導地位。詳細結果預計將在未來的醫學會議上分享。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
